Paper Details
- Home
- Paper Details
A High-Content Screening of Anticancer Compounds Suggests the Multiple Tyrosine Kinase Inhibitor Ponatinib for Repurposing in Neuroblastoma Therapy.
Author: AdamiValentina, AveicSanja, AvitabileMarianna, CapassoMario, CilliMichele, CimminoFlora, CroceMichela, De MarianoMarilena, EmioniteLaura, FerriniSilvano, GattoPamela, LongoLuca, PaganoAldo, PancherMichael, ParodiFederica, PasiniLuigi, PizziniSilvia, QuattroneAlessandro, SidarovichViktoryia, ToniniGian Paolo
Original Abstract of the Article :
Novel druggable targets have been discovered in neuroblastoma (NB), paving the way for more effective treatments. However, children with high-risk NB still show high mortality rates prompting for a search of novel therapeutic options. Here, we aimed at repurposing FDA-approved drugs for NB treatment...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://doi.org/10.1158/1535-7163.MCT-17-0841
データ提供：米国国立医学図書館（NLM）
Repurposing Drugs for Neuroblastoma Treatment
Neuroblastoma, a type of childhood cancer, is like a desert sandstorm, threatening the health of young patients. This research explores the potential of repurposing existing FDA-approved drugs to combat neuroblastoma, offering a new avenue for treating this challenging disease. It's like a camel caravan searching for a hidden oasis of treatment options in the vast desert of cancer research.
The researchers conducted a high-content screening of a library of anticancer compounds, identifying ponatinib, a multiple tyrosine kinase inhibitor, as a promising candidate for repurposing in neuroblastoma therapy. This research is like finding a hidden spring in the desert, offering a new and potentially effective approach to treating neuroblastoma. The study found that ponatinib effectively inhibited tumor growth in mice, suggesting its potential for clinical use.
A New Oasis in the Desert of Neuroblastoma Treatment
This research highlights the potential of repurposing existing FDA-approved drugs for neuroblastoma treatment. The findings suggest that ponatinib, a multiple tyrosine kinase inhibitor, may offer a new and effective treatment option for this challenging disease. This research is like finding a new path through the desert, leading to potentially better treatment outcomes for neuroblastoma patients.
Hope on the Horizon for Neuroblastoma Treatment
This research offers a glimmer of hope for neuroblastoma patients by identifying ponatinib, an FDA-approved drug, as a potential treatment option. The study's findings may lead to new clinical trials and potentially improve treatment outcomes for children diagnosed with this challenging disease. It's like discovering a new oasis in the desert, providing a source of hope and potentially effective treatment for neuroblastoma.
Dr.Camel's Conclusion
This research provides exciting insights into the potential of repurposing existing FDA-approved drugs for neuroblastoma treatment. The findings suggest that ponatinib may offer a new and effective treatment option for this challenging disease, potentially leading to improved outcomes for children diagnosed with neuroblastoma.
Date :
- Date Completed 2019-07-12
- Date Revised 2020-09-30
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.